Weekly low-dose doxorubicin with or without high-dose medroxyprogesterone acetate as secondary treatment in metastatic breast cancer--a randomized trial

Acta Oncol. 1988;27(3):297-9. doi: 10.3109/02841868809093543.

Authors

I Elomaa¹, C Blomqvist, P Rissanen, M Mäntylä

Affiliation

¹ Department of Radiotherapy and Oncology, University of Helsinki, Finland.

PMID: 2970862
DOI: 10.3109/02841868809093543

No abstract available

Publication types

Case Reports
Clinical Trial
Randomized Controlled Trial

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Clinical Trials as Topic
Doxorubicin / administration & dosage
Female
Humans
Medroxyprogesterone / administration & dosage
Medroxyprogesterone / analogs & derivatives
Medroxyprogesterone Acetate
Middle Aged
Neoplasm Metastasis
Random Allocation

Substances

Doxorubicin
Medroxyprogesterone Acetate
Medroxyprogesterone